228 related articles for article (PubMed ID: 30156768)
1. Ancillary studies in pleural, pericardial, and peritoneal effusion cytology.
Sundling KE; Cibas ES
Cancer Cytopathol; 2018 Aug; 126 Suppl 8():590-598. PubMed ID: 30156768
[TBL] [Abstract][Full Text] [Related]
2. Special stains, the old and the new: the impact of immunocytochemistry in effusion cytology.
Bedrossian CW
Diagn Cytopathol; 1998 Feb; 18(2):141-9. PubMed ID: 9484644
[No Abstract] [Full Text] [Related]
3. [Evaluation of immunohistochemistry staining and cytologic diagnosis by using cell block sections prepared with effusion fluid cytology specimens].
Mao YY; Yang M; Liu DG; Lin MH; Zhang LQ; Chen ZQ
Zhonghua Bing Li Xue Za Zhi; 2009 Aug; 38(8):547-50. PubMed ID: 20021967
[TBL] [Abstract][Full Text] [Related]
4. Small orangiophilic squamous-like cells: an underrecognized and useful morphological feature for the diagnosis of malignant mesothelioma in pleural effusion cytology.
Chen L; Caldero SG; Gmitro S; Smith ML; De Petris G; Zarka MA
Cancer Cytopathol; 2014 Jan; 122(1):70-5. PubMed ID: 23983174
[TBL] [Abstract][Full Text] [Related]
5. Serous effusions in malignant lymphomas: a review.
Das DK
Diagn Cytopathol; 2006 May; 34(5):335-47. PubMed ID: 16604559
[TBL] [Abstract][Full Text] [Related]
6. Cytohistological correlation in serous effusions using the newly proposed International System for Reporting Serous Fluid Cytopathology: Experience of an oncological center.
Lobo C; Costa J; Petronilho S; Monteiro P; Leça L; Schmitt F
Diagn Cytopathol; 2021 May; 49(5):596-605. PubMed ID: 32339444
[TBL] [Abstract][Full Text] [Related]
7. Role of Ancillary Techniques in Fluid Cytology.
Yu GH; Glaser LJ; Gustafson KS
Acta Cytol; 2020; 64(1-2):52-62. PubMed ID: 31018204
[TBL] [Abstract][Full Text] [Related]
8. Morphologic and immunocytochemical performances of effusion cell blocks prepared using 3 different methods.
Jing X; Li QK; Bedrossian U; Michael CW
Am J Clin Pathol; 2013 Feb; 139(2):177-82. PubMed ID: 23355202
[TBL] [Abstract][Full Text] [Related]
9. IMP3/L523S, a novel immunocytochemical marker that distinguishes benign and malignant cells: the expression profiles of IMP3/L523S in effusion cytology.
Ikeda K; Tate G; Suzuki T; Kitamura T; Mitsuya T
Hum Pathol; 2010 May; 41(5):745-50. PubMed ID: 20060157
[TBL] [Abstract][Full Text] [Related]
10. Malignancies in Pleural, Peritoneal, and Pericardial Effusions.
Dermawan JKT; Policarpio-Nicolas ML
Arch Pathol Lab Med; 2020 Sep; 144(9):1086-1091. PubMed ID: 31913661
[TBL] [Abstract][Full Text] [Related]
11. Testing for BAP1 loss and CDKN2A/p16 homozygous deletion improves the accurate diagnosis of mesothelial proliferations in effusion cytology.
Chevrier M; Monaco SE; Jerome JA; Galateau-Salle F; Churg A; Dacic S
Cancer Cytopathol; 2020 Dec; 128(12):939-947. PubMed ID: 32678499
[TBL] [Abstract][Full Text] [Related]
12. Detection of cancer cells in effusions from patients diagnosed with gynaecological malignancies. Evaluation of five epithelial markers.
Davidson B; Risberg B; Kristensen G; Kvalheim G; Emilsen E; Bjåmer A; Berner A
Virchows Arch; 1999 Jul; 435(1):43-9. PubMed ID: 10431845
[TBL] [Abstract][Full Text] [Related]
13. Cytomorphological profile of neoplastic effusions: an audit of 10 years with emphasis on uncommonly encountered malignancies.
Gupta S; Sodhani P; Jain S
J Cancer Res Ther; 2012; 8(4):602-9. PubMed ID: 23361282
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic usefulness of EMA, IMP3, and GLUT-1 for the immunocytochemical distinction of malignant cells from reactive mesothelial cells in effusion cytology using cytospin preparations.
Ikeda K; Tate G; Suzuki T; Kitamura T; Mitsuya T
Diagn Cytopathol; 2011 Jun; 39(6):395-401. PubMed ID: 21574259
[TBL] [Abstract][Full Text] [Related]
15. Comparison of immunocytochemical sensitivity between formalin-fixed and alcohol-fixed specimens reveals the diagnostic value of alcohol-fixed cytocentrifuged preparations in malignant effusion cytology.
Ikeda K; Tate G; Suzuki T; Mitsuya T
Am J Clin Pathol; 2011 Dec; 136(6):934-42. PubMed ID: 22095380
[TBL] [Abstract][Full Text] [Related]
16. Reliably making the primary diagnosis of mesothelioma utilizing serous fluid cytology specimens: an institutional experience.
Jones TE; Geisler DL; Baskota SU; Ohori NP; Cuda J; Khader SN
J Am Soc Cytopathol; 2024; 13(3):174-182. PubMed ID: 38514361
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis and categorization of malignant effusions: A 6-year review from a single academic institution.
Lew M; Cantley R; Heider A; Jing X
Diagn Cytopathol; 2021 May; 49(5):615-621. PubMed ID: 32275354
[TBL] [Abstract][Full Text] [Related]
18. GATA3: a promising marker for metastatic breast carcinoma in serous effusion specimens.
Shield PW; Papadimos DJ; Walsh MD
Cancer Cytopathol; 2014 Apr; 122(4):307-12. PubMed ID: 24421220
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic Value of the EZH2 Immunomarker in Malignant Effusion Cytology.
Ang PP; Tan GC; Karim N; Wong YP
Acta Cytol; 2020; 64(3):248-255. PubMed ID: 31352449
[TBL] [Abstract][Full Text] [Related]
20. Positive effusion cytology as the initial presentation of malignancy.
Monte SA; Ehya H; Lang WR
Acta Cytol; 1987; 31(4):448-52. PubMed ID: 3604540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]